Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Patent
1993-05-12
1995-11-21
Scheiner, Toni R.
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
436 87, 436510, 436518, 436814, G01N 33543
Patent
active
054686199
ABSTRACT:
The present invention provides an early, biochemical indication of increased risk of impending delivery. The method is particularly useful to identify those pregnant women who are at increased risk for preterm delivery and can also be used to identify those women at risk for a post-date delivery. The method comprises obtaining a cervicovaginal secretion sample from a pregnant patient after week 12 of gestation and determining the level of total fibronectin in the sample. The presence of an elevated fibronectin level in the sample indicates an increased risk of delivery. The test detects greater than 80% of women who deliver prematurely, as early as two to three weeks prior to delivery.
REFERENCES:
patent: 5096830 (1992-03-01), Senyei et al.
Leveno et al, W. Obstetrics Suppl, 12:1-11 (1987).
Oellerich, M., J. Clin. Chem. Clin. Biochem., 22:895-904 (1984).
Wisdom, B. Clin. Chem., 22:1243-1255 (1976).
Sekiguchi et al, J. Biological Chem., 260:5105-5114 (1985).
Hayashi et al. J. Biological Chem., 256:11292-11300 (1981).
Atherton et al, Cell, 25:133-141 (1981).
Kuusela et al, Scand. J. Immunol., 12:331-337 (1980).
Matsuura et al, Proc. Natl. Acad. Sci. USA, 82:6517-6521 (1985).
Hess et al, Obstet. Gynecol. 68:25-28 (1986).
Ruoslahti et al, Int. J. Cancer, 27:763-767 (1981).
Lockwood et al,, "Increased plasma levels of EDI.sup.+ cellular fibronectin precede the clinical signs of preeclampsia," Am. J. Gynecol. 162:358-362 (1990).
Lockwood et al-The New England J. of Med. vol. 325 No. 10 Sep. 5, 1991 pp. 669-674.
Atunkova et al-Chem Abst. vol. 115 (1991) pp. 205, 588b.
Bala et al, Aust NZ Obstet. Gynecol, 26:141-144 (1986).
Casal David C.
Senyei Andrew E.
Adeza Biomedical Corporation
Grun James L.
Haliday Emily M.
Scheiner Toni R.
Terlizzi Laura
LandOfFree
Screening method for identifying women at increased risk for imm does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Screening method for identifying women at increased risk for imm, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Screening method for identifying women at increased risk for imm will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1136191